Dyne Therapeutics, Inc.
1560 Trapelo Road
Waltham, MA 02451
November 15, 2021
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Michael Davis
Re: Dyne Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-260755
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dyne Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-260755), so that it may become effective at 4:00 p.m., Eastern time, on November 17, 2021, or as soon as practicable thereafter.
| Very truly yours, | ||||
| DYNE THERAPEUTICS, INC. | ||||
| By: | /s/ Joshua Brumm | |||
| Name: | Joshua Brumm | |||
| Title: | President and Chief Executive Officer | |||